Correlation between miRseq expression and clinical features
Brain Lower Grade Glioma (Primary solid tumor)
17 October 2014  |  analyses__2014_10_17
Maintainer Information
Citation Information
Maintained by Juok Cho (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2014): Correlation between miRseq expression and clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1GQ6WPN
Overview
Introduction

This pipeline uses various statistical tests to identify miRs whose log2 expression levels correlated to selected clinical features.

Summary

Testing the association between 548 miRs and 8 clinical features across 430 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 6 clinical features related to at least one miRs.

  • 101 miRs correlated to 'Time to Death'.

    • HSA-MIR-155 ,  HSA-MIR-10A ,  HSA-MIR-15B ,  HSA-MIR-148A ,  HSA-MIR-196B ,  ...

  • 41 miRs correlated to 'AGE'.

    • HSA-MIR-34A ,  HSA-MIR-155 ,  HSA-MIR-10B ,  HSA-MIR-25 ,  HSA-MIR-146A ,  ...

  • 19 miRs correlated to 'KARNOFSKY.PERFORMANCE.SCORE'.

    • HSA-MIR-222 ,  HSA-MIR-148A ,  HSA-MIR-181A-2 ,  HSA-MIR-432 ,  HSA-MIR-135B ,  ...

  • 107 miRs correlated to 'HISTOLOGICAL.TYPE'.

    • HSA-MIR-1262 ,  HSA-MIR-186 ,  HSA-MIR-219-1 ,  HSA-MIR-592 ,  HSA-MIR-576 ,  ...

  • 56 miRs correlated to 'RADIATIONS.RADIATION.REGIMENINDICATION'.

    • HSA-MIR-1274B ,  HSA-MIR-628 ,  HSA-MIR-3130-1 ,  HSA-MIR-9-3 ,  HSA-MIR-30E ,  ...

  • 1 miR correlated to 'RACE'.

    • HSA-MIR-1304

  • No miRs correlated to 'GENDER', and 'ETHNICITY'.

Results
Overview of the results

Complete statistical result table is provided in Supplement Table 1

Table 1.  Get Full Table This table shows the clinical features, statistical methods used, and the number of miRs that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.

Clinical feature Statistical test Significant miRs Associated with                 Associated with
Time to Death Cox regression test N=101 shorter survival N=96 longer survival N=5
AGE Spearman correlation test N=41 older N=32 younger N=9
GENDER Wilcoxon test   N=0        
KARNOFSKY PERFORMANCE SCORE Spearman correlation test N=19 higher score N=1 lower score N=18
HISTOLOGICAL TYPE Kruskal-Wallis test N=107        
RADIATIONS RADIATION REGIMENINDICATION Wilcoxon test N=56 yes N=56 no N=0
RACE Kruskal-Wallis test N=1        
ETHNICITY Wilcoxon test   N=0        
Clinical variable #1: 'Time to Death'

101 miRs related to 'Time to Death'.

Table S1.  Basic characteristics of clinical feature: 'Time to Death'

Time to Death Duration (Months) 0-211.2 (median=15.8)
  censored N = 354
  death N = 74
     
  Significant markers N = 101
  associated with shorter survival 96
  associated with longer survival 5
List of top 10 miRs differentially expressed by 'Time to Death'

Table S2.  Get Full Table List of top 10 miRs significantly associated with 'Time to Death' by Cox regression test

HazardRatio Wald_P Q C_index
HSA-MIR-155 1.96 0 0 0.805
HSA-MIR-10A 1.34 2.802e-12 1.5e-09 0.729
HSA-MIR-15B 2 4.946e-12 2.7e-09 0.797
HSA-MIR-148A 1.65 8.413e-11 4.6e-08 0.767
HSA-MIR-196B 1.24 1.876e-10 1e-07 0.732
HSA-MIR-9-1 0.39 3.472e-09 1.9e-06 0.231
HSA-MIR-9-2 0.39 3.511e-09 1.9e-06 0.231
HSA-MIR-346 0.62 1.534e-08 8.3e-06 0.37
HSA-MIR-23A 1.96 1.585e-08 8.6e-06 0.733
HSA-MIR-142 1.67 2.849e-08 1.5e-05 0.727
Clinical variable #2: 'AGE'

41 miRs related to 'AGE'.

Table S3.  Basic characteristics of clinical feature: 'AGE'

AGE Mean (SD) 42.94 (13)
  Significant markers N = 41
  pos. correlated 32
  neg. correlated 9
List of top 10 miRs differentially expressed by 'AGE'

Table S4.  Get Full Table List of top 10 miRs significantly correlated to 'AGE' by Spearman correlation test

SpearmanCorr corrP Q
HSA-MIR-34A 0.2988 2.677e-10 1.47e-07
HSA-MIR-155 0.2637 2.956e-08 1.62e-05
HSA-MIR-10B 0.2575 6.342e-08 3.46e-05
HSA-MIR-25 0.2575 6.349e-08 3.46e-05
HSA-MIR-146A 0.255 8.534e-08 4.64e-05
HSA-MIR-10A 0.2492 1.698e-07 9.22e-05
HSA-MIR-126 0.244 3.112e-07 0.000169
HSA-MIR-2115 0.2447 8.293e-07 0.000449
HSA-MIR-320B-2 0.2333 1.033e-06 0.000558
HSA-MIR-16-1 0.2189 4.746e-06 0.00256
Clinical variable #3: 'GENDER'

No miR related to 'GENDER'.

Table S5.  Basic characteristics of clinical feature: 'GENDER'

GENDER Labels N
  FEMALE 192
  MALE 238
     
  Significant markers N = 0
Clinical variable #4: 'KARNOFSKY.PERFORMANCE.SCORE'

19 miRs related to 'KARNOFSKY.PERFORMANCE.SCORE'.

Table S6.  Basic characteristics of clinical feature: 'KARNOFSKY.PERFORMANCE.SCORE'

KARNOFSKY.PERFORMANCE.SCORE Mean (SD) 87.74 (12)
  Significant markers N = 19
  pos. correlated 1
  neg. correlated 18
List of top 10 miRs differentially expressed by 'KARNOFSKY.PERFORMANCE.SCORE'

Table S7.  Get Full Table List of top 10 miRs significantly correlated to 'KARNOFSKY.PERFORMANCE.SCORE' by Spearman correlation test

SpearmanCorr corrP Q
HSA-MIR-222 -0.255 4.838e-05 0.0265
HSA-MIR-148A -0.2524 5.828e-05 0.0319
HSA-MIR-181A-2 0.2499 6.924e-05 0.0378
HSA-MIR-432 -0.2466 8.694e-05 0.0474
HSA-MIR-135B -0.2634 0.0001036 0.0564
HSA-MIR-493 -0.2455 0.0001178 0.064
HSA-MIR-187 -0.2377 0.0002279 0.124
HSA-MIR-103-2 -0.2318 0.0002312 0.125
HSA-MIR-134 -0.2294 0.0002691 0.145
HSA-MIR-337 -0.2287 0.0002819 0.152
Clinical variable #5: 'HISTOLOGICAL.TYPE'

107 miRs related to 'HISTOLOGICAL.TYPE'.

Table S8.  Basic characteristics of clinical feature: 'HISTOLOGICAL.TYPE'

HISTOLOGICAL.TYPE Labels N
  ASTROCYTOMA 158
  OLIGOASTROCYTOMA 106
  OLIGODENDROGLIOMA 166
     
  Significant markers N = 107
List of top 10 miRs differentially expressed by 'HISTOLOGICAL.TYPE'

Table S9.  Get Full Table List of top 10 miRs differentially expressed by 'HISTOLOGICAL.TYPE'

ANOVA_P Q
HSA-MIR-1262 1.592e-17 8.72e-15
HSA-MIR-186 4.075e-16 2.23e-13
HSA-MIR-219-1 1.346e-15 7.35e-13
HSA-MIR-592 3.202e-15 1.75e-12
HSA-MIR-576 6.813e-15 3.71e-12
HSA-MIR-3065 1.183e-14 6.42e-12
HSA-MIR-3074 3.451e-13 1.87e-10
HSA-MIR-505 3.619e-13 1.96e-10
HSA-MIR-301A 1.691e-12 9.13e-10
HSA-MIR-21 3.645e-12 1.96e-09
Clinical variable #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

56 miRs related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.

Table S10.  Basic characteristics of clinical feature: 'RADIATIONS.RADIATION.REGIMENINDICATION'

RADIATIONS.RADIATION.REGIMENINDICATION Labels N
  NO 88
  YES 342
     
  Significant markers N = 56
  Higher in YES 56
  Higher in NO 0
List of top 10 miRs differentially expressed by 'RADIATIONS.RADIATION.REGIMENINDICATION'

Table S11.  Get Full Table List of top 10 miRs differentially expressed by 'RADIATIONS.RADIATION.REGIMENINDICATION'

W(pos if higher in 'YES') wilcoxontestP Q AUC
HSA-MIR-1274B 7213 2.004e-12 1.1e-09 0.7447
HSA-MIR-628 8403 1.649e-10 9.02e-08 0.7208
HSA-MIR-3130-1 7170 3.865e-10 2.11e-07 0.7242
HSA-MIR-9-3 21069 7.01e-09 3.82e-06 0.7001
HSA-MIR-30E 9290 3.064e-08 1.67e-05 0.6913
HSA-MIR-331 9333 3.877e-08 2.11e-05 0.6899
HSA-MIR-3677 9602 1.626e-07 8.82e-05 0.681
HSA-MIR-424 9640 1.981e-07 0.000107 0.6797
HSA-MIR-296 9868 6.3e-07 0.00034 0.6721
HSA-MIR-500A 20228 6.3e-07 0.00034 0.6721
Clinical variable #7: 'RACE'

One miR related to 'RACE'.

Table S12.  Basic characteristics of clinical feature: 'RACE'

RACE Labels N
  AMERICAN INDIAN OR ALASKA NATIVE 1
  ASIAN 6
  BLACK OR AFRICAN AMERICAN 14
  WHITE 400
     
  Significant markers N = 1
List of one miR differentially expressed by 'RACE'

Table S13.  Get Full Table List of one miR differentially expressed by 'RACE'

ANOVA_P Q
HSA-MIR-1304 6.547e-05 0.0359
Clinical variable #8: 'ETHNICITY'

No miR related to 'ETHNICITY'.

Table S14.  Basic characteristics of clinical feature: 'ETHNICITY'

ETHNICITY Labels N
  HISPANIC OR LATINO 16
  NOT HISPANIC OR LATINO 387
     
  Significant markers N = 0
Methods & Data
Input
  • Expresson data file = LGG-TP.miRseq_RPKM_log2.txt

  • Clinical data file = LGG-TP.merged_data.txt

  • Number of patients = 430

  • Number of miRs = 548

  • Number of clinical features = 8

Survival analysis

For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels

Correlation analysis

For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R

Student's t-test analysis

For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R

ANOVA analysis

For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Andersen and Gill, Cox's regression model for counting processes, a large sample study, Annals of Statistics 10(4):1100-1120 (1982)
[2] Spearman, C, The proof and measurement of association between two things, Amer. J. Psychol 15:72-101 (1904)
[3] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[4] Howell, D, Statistical Methods for Psychology. (5th ed.), Duxbury Press:324-5 (2002)
[5] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)